Bacteria in cancer therapy: A novel experimental strategy

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Patyar, S ^a   Joshi, R ^a   Byrav, D S Prasad ^a   Prakash, A ^a   Medhi, B ^a   Das, B K ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BACTERIAL VECTOR; BCG VACCINE; CLOSTRIDIUM NOVYI NT VACCINE; COMBRETASTATIN A4 PHOSPHATE; CYTOSINE DEAMINASE; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; DRUG CARRIER; ENDOSTATIN; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MAC 321; MITOMYCIN C; MOLECULAR THERAPY AGENT; NAVELBINE; NITROREDUCTASE; TALTOBULIN; TAXANE DERIVATIVE; THROMBOCYTE FACTOR 4; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; PRODRUG; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; BACTERIAL GENE; BACTERIAL SPORE; BACTERIAL STRAIN; BIFIDOBACTERIUM ADOLESCENTIS; BLADDER CANCER; CANCER CELL; CANCER MODEL; CLINICAL TRIAL; CLOSTRIDIUM; CLOSTRIDIUM M55; COMBINATION BACTERIOLYTIC THERAPY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE VECTOR; HUMAN; LEWIS CARCINOMA; LISTERIA MONOCYTOGENES; MOLECULAR THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; SALMONELLA CHOLERAESUIS; SALMONELLA TYPHIMURIUM; SOLID TUMOR; TUMOR; TUMOR AMPLIFIED PROTEIN EXPRESSION THERAPY; VIBRIO CHOLERAE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; ENZYMOLOGY; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY;

BACTERIA (MICROORGANISMS);

ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL TOXINS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PRODRUGS;

EID: 77950940044     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-21     Document Type: Review

References (64)

1. New approaches for the treatment of cancer. RK Jain, Adv Drug Delivery Rev 2001 46 149 168 10.1016/S0169-409X(00)00131-9
2. Recent progress in the battle between oncolytic viruses and tumours. KA Parato D Senger PA Forsyth JC Bell, Nat Rev Cancer 2005 5 965 976 10.1038/nrc1750 16294217 (Pubitemid 41766784)
3. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. H Nauts G Fowler F Bogatko, Acta Medica Scandinavica 1953 276 1 103 13039964
4. The beneficial effects of bacterial infections on host resistance to cancer: End result in 449 cases. HC Nauts, Cancer research institute monograph no. 8, New York, USA 2 1980
5. Coley toxins immunotherapy: a retrospective review. MA Richardson T Ramirez NC Russell LA Moye, Altern Ther Health Med 1999 5 42 47 10234867
6. Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer? LR Zacharski VP Sukhatme, Journal of Thrombosis and Haemostasis 2005 3 424 10.1111/j.1538-7836.2005.01110.x 15748226
7. Dr. William Coley and tumour regression: a place in history or in the future. SA Hoption Cann JP van Netten C van Netten, Postgrad Med J 2003 79 672 680 14707241 (Pubitemid 38134682)
8. Coley's toxins-the first century. HC Nauts McLaren, Adv Exp Med Bio 1990 267 483 500
9. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. RA Malmgren CC Flanigan, Cancer Res 1955 15 473 478 13240693
10. An endotoxin-induced serum factor that causes necrosis of tumors. EA Carswell LJ Old RL Kassel S Green N Fiore B Williamson, Proc Natl Acad Sci 1975 72 3666 3670 10.1073/pnas.72.9.3666 1103152
11. Clostridia in cancer therapy. NP Minton, Nat Rev Microbiol 2003 1 237 242 10.1038/nrmicro777 15035028
12. Clostridial oncolysis in man. R Carey J Holland H Whang E Neter B Bryant, Eur J Cancer 1967 3 37 46
13. Combination bacteriolytic therapy for the treatment of experimental tumors. LH Dang C Bettegowda DL Huso KW Kinzler B Vogelstein, Proc Natl Acad Sci 2001 98 26 15155 15160 10.1073/pnas.251543698 11724950
14. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. C Bettegowda LH Dang R Abrams DL Huso L Dillehay I Cheong N Agrawal S Borzillary JM McCaffery EL Watson KS Lin F Bunz K Baidoo MG Pomper KW Kinzler B Vogelstein S Zhou, Proc Natl Acad Sci 2003 100 25 15083 15088 10.1073/pnas.2036598100 14657371
15. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. MQ Wei KAO Ellem P Dunn MJ West CX Bai B Vogelstein, Eur J Cancer 2007 43 490 496 10.1016/j.ejca.2006.10.005 17113280
16. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. I Cheong X Huang C Bettegowda LA Diaz Jr KW Kinzler S Zhou B Vogelstein, Science 2006 314 5803 1308 1311 10.1126/science.1130651 17124324
17. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. LH Dang C Bettegowda N Agrawal I Cheong D Huso P Frost F Loganzo L Greenberger J Barkoczy GR Pettit AB Smith H Gurulingappa S Khan G Parmigiani KW Kinzler S Zhou B Vogelstein, Cancer Biol Ther 2004 3 3 326 337 14739784
18. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors. KB Low M Ittensohn S Lin C Clairmont X Luo L-M Zheng I King JM Pawelek, Proc Am Assoc Cancer Res 1999 40 851
19. Genetically modified Salmonella typhimurium inhibited growth of primary tumors and metastase. X Luo M Ittensohn B Low J Pawelek Z Li X Ma D Bermudes, Proc Annu Meet Am Assoc Cancer Res 1999 40 3146
20. Live bacteria as anticancer agents and tumor-selective protein delivery vectors. D Bermudes L Zheng IC King, Curr Opin Drug Discov Devel 2002 5 2 194 199 11926125
21. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent. DA Saltzman CP Heise DE Hasz M Zebede SM Kelly R Curtiss, Cancer Biother Radiopharm 1996 11 145 153 10.1089/cbr.1996.11.145 10851531 (Pubitemid 126521022)
22. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: A novel anti-tumor agent. DA Saltzman E Katsanis CP Heise DE Hasz SM Kelly R Curtiss, Cancer Biother Radiopharm 1997 12 37 45 10.1089/cbr.1997.12.37 10851445 (Pubitemid 27150029)
23. Tumor-directed delivery and amplification of tumor-necrosis factor- (TNF) by attenuated Salmonella typhimurium. SL Lin TL Spinka TX Le TJM Pianta I King MF Belcourt Z Li, Clinical Cancer Res 1999 5 3822
24. A strain of Salmonella typhimurium VNP20009 expressing an anti-angiogenic peptide from platelet factor-4 has enhanced anti-tumor activity. V Karsten J Pike K Troy X Luo L-M Zheng I King D Bermudes, Proc Annu Meet Am Assoc Cancer Res 2001 42 3700
25. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. L Yuhua G Kunyuan C Hui X Yongmei S Chaoyang R Daming, Int J Cancer 2001 94 438 443 10.1002/ijc.1489 11745427 (Pubitemid 32906078)
26. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. X Li GF Fu YR Fan WH Liu XJ Liu, Cancer Gene Ther 2003 10 105 111 10.1038/sj.cgt.7700530 12536198 (Pubitemid 36228257)
27. Clostridia in Anti-tumor Therapy. Mengesha, et al. Clostridia: Molecular Biology in the Post-genomic Era Caister Academic Press, Bruggemann H, Gottschalk G, 2009
28. Specific targeting of cytosine deaminasto solid tumors by engineered Clostridium acetobutylicum. J Theys W Landuyt S Nuyts L Van Mellaert A van Oosterom P Lambin J Anne, Cancer Gene Ther 2001 8 294 297 10.1038/sj.cgt.7700303 11393282 (Pubitemid 32480066)
29. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. SC Liu NP Minton AJ Giaccia JM Brown, Gene Ther 2002 9 291 296 10.1038/sj.gt.3301659 11896468
30. Genetically armed Salmonella typhimurium delivered therapeutic gene and inhibited tumor growth in preclinical models. X Luo Z Li SY Shen JD Runyan D Bermudes LM Zheng, Proc Annu Meet Am Assoc Cancer Res 2001 42 3693
31. Tumor-targeted Salmonella as a novel anticancer vector. JM Pawelek KB Low D Bermudes, Cancer Res 1997 57 4537 4544 9377566 (Pubitemid 27441058)
32. Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Tjuvajev R Blasberg X Luo LM Zheng I King D Bermudes, J Control Release 2001 74 313 315 10.1016/S0168-3659(01)00340-6 11489512 (Pubitemid 32727638)
33. The genus Bifidobacterium for cancer gene therapy. M Fujimori J Amano S Taniguchi, Curr Opin Drug Discov Devel 2003 5 200 203
34. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. JP Nougayrede F Taieb J De Rycke E Oswald, Trends Microbiol 2005 13 103 110 10.1016/j.tim.2005.01.002 15737728 (Pubitemid 40311892)
35. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. E Oswald M Sugai A Labigne HC Wu C Fiorentini P Boquet AD O'Brien, Proc Natl Acad Sci 1994 91 3814 3818 10.1073/pnas.91.9.3814 8170993
36. Toxin-induced activation of Rho GTP-binding protein increases Bcl-2 expression and influences mitochondrial homeostasis. C Fiorentini P Matarrese E Straface L Falzano A Fabbri G Donelli, Exp Cell Res 1998 242 341 350 10.1006/excr.1998.4057 9665831
37. Crystal structure of the comlex of diphtheria toxin with an extracellular fragment of its receptor. GV Louie W Yang ME Bowman S Choe, Mol Cell 1997 1 67 68 10.1016/S1097-2765(00)80008-8 9659904
38. Diphtheria fusion protein therapy of chemoresistant malignancies. AE Frankel P Rossi TM Kuzel F Foss, Curr Cancer Drug Targets 2002 2 19 36 10.2174/1568009023333944 12188918
39. GPI-anchored diphtheria toxin receptor allows membrane translocation of the toxin without detectable ion channel activity. M Lanzerin O Sand S Olsnes, EMBO J 1996 15 725 734 8631294
40. Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin. PO Falnes S Ariansen K Sandwig S Olsnes, J Biol Chem 2000 275 4363 4368 10.1074/jbc.275.6.4363 10660606
41. Targeted therapy of cancer with recombinant immunotoxins. I Pastan, Biochim Biophys Acta 1997 1333 1 C6 9395287
42. Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis. JF Kokai Kun BA Mcclane, Clin Infect Dis 1997 25 165 S167 10.1086/516246 9310665
43. Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. JF Kokai Kun K Benton EU Wieckowski BA Mcclane, Infect Immun 1999 67 5634 5641 10531210 (Pubitemid 29508080)
44. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. P Michl M Buchholz M Rolke, Gasrtoenterology 2001 121 678 684 10.1053/gast.2001.27124 (Pubitemid 32822583)
45. Large scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. CD Hough CA Sherman Baust ES Pizer, Cancer Res 2000 60 6281 6287 11103784
46. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. SL Kominsky M Vali D Korz, Am J Pathol 2004 164 1627 1633 15111309 (Pubitemid 38529765)
47. Use of botulinum toxins in cancer therapy. R Ansiaux B Gallez, Expert Opin Investig Drugs 2007 16 2 209 218 10.1517/13543784.16.2.209 17243940 (Pubitemid 46206634)
48. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM 107. N Hagihara S Walbridge AW Olson EH Oldfield RJ Youle, Cancer Res 2000 60 230 234 10667564
49. Targeted therapy against human lung cancer in nude mice by high affinity recombinant antimesothelin single chain Fv immunotoxin. D Fan S Yano H Shinohara C Solorzano, Mol Cancer Ther 2002 1 595 600 12479219
50. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. L Greenfield VG Johnson RJ Youle, Science 1987 238 536 539 10.1126/science.3498987 3498987
51. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. RK Puri, Toxicol Pathol 1999 27 1 53 57 10.1177/019262339902700111 10367674
52. Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours. J Xu XS Liu SF Zhou MQ Wei, Gene Ther Mol Biol 2009 13 36 52
53. Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. F Avogadri C Martinoli L Petrovska C Chiodoni P Transidico V Bronte R Longhi MP Colombo G Dougan M Rescigno, Cancer Res 2005 65 9 3920 3927 10.1158/0008-5472.CAN-04-3002 15867392
54. Attenuated Bacteria as Effectors in Cancer Immunotherapy. BK Al-Ramadi MJ Fernandez-Cabezudo H El-Hasasna S Al-Salam S Attoub D Xu S Chouaib, Ann N Y Acad Sci 2008 1138 1 351 357 10.1196/annals.1414.036 18837910
55. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Z Ruan Z Yang Y Wang H Wang Y Chen X Shang C Yang S Guo J Han H Liang Y Wu, J Immunother 2009 32 5 486 491 10.1097/CJI.0b013e3181a1d134 19609240
56. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. LM Wood PD Guirnalda MM Seavey Y Paterson, Immunol Res 2008 42 233 245 10.1007/s12026-008-8087-0 19018479
57. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. SH Kim F Castro Y Paterson C Gravekamp, Cancer Res 2009 69 14 5860 5866 10.1158/0008-5472.CAN-08-4855 19584282
58. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. M Loeffler G Le'Negrate M Krajewska JC Reed, Proc Natl Acad Sci 2007 104 31 12879 12883 10.1073/pnas.0701959104 17652173
59. Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: effect of lymphadenectomy. A Hayashi Y Nishida S Yoshii SY Kim H Uda T Hamasaki, Cancer Sci 2009 100 10 1991 1995 10.1111/j.1349-7006.2009.01271.x 19656158
60. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. JM Yuk DM Shin KS Song K Lim KH Kim SH Lee JM Kim JS Lee TH Paik JS Kim EK Jo, Autophagy 2010 6 1 46 60 19901560
61. Oncolysis by Clostridia IV effect of nonpathogenic Clostridial spores in normal and pathological tissues. E Thiele R Arison G Boxer, Cancer Res 1963 24 234 238
62. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. LA Diaz Jr I Cheong CA Foss X Zhang BA Peters N Agrawal, et al. Toxicol Sci 2005 88 2 562 575 10.1093/toxsci/kfi316 16162850
63. Perspectives in vector development for systemic cancer gene therapy. A Hatefi BF Canine, Gene Ther Mol Biol 2009 13 A 15 19 19503758
64. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. I King M Itterson D Bermudes, Methods Mol Biol 2009 542 649 659 full-text 19565926